Loading
NASDAQHealthcareBiotechnology
Latest quote
$14.97
+$0.27 · +1.84%
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Previous close
$14.97
+$0.27 · +1.84%
Regular session · ET · Market data may be delayed.
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Day range
Current $14.97
52-week range
Current $14.97
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
64
Undervalued
Sentiment
74
Bullish
Risk
62
High Risk
Momentum
66
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Day range
Current $14.97
52-week range
Current $14.97
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 85.21M USD | 37K USD | 20.72M USD | 3.13M USD | 18.04M USD |
| Cost of goods sold | 7.63M USD | 141.3M USD | 97.1M USD | 80.25M USD | 61.36M USD |
| Gross profit | 77.58M USD | −141.26M USD | −76.37M USD | −77.12M USD | −43.32M USD |
| Research and development | 195.7M USD | 141.3M USD | 97.1M USD | 80.25M USD | 61.36M USD |
| Selling, general, and administrative | 49.06M USD | 46.58M USD | 36.49M USD | 32.91M USD | 28.01M USD |
| Operating expenses | 237.13M USD | 46.58M USD | 36.49M USD | 32.91M USD | 28.01M USD |
| Interest income | 19.48M USD | 27.05M USD | 12.21M USD | 2.57M USD | 137K USD |
| Depreciation and amortization | 7.63M USD | 6.71M USD | 4.2M USD | 2.4M USD | 1.52M USD |
| Operating income | −159.55M USD | −187.84M USD | −112.87M USD | −110.03M USD | −71.33M USD |
| Net income | −140.11M USD | −160.87M USD | −100.84M USD | −107.49M USD | −71.32M USD |
Company facts updated Sep 6, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI25.22M0.22%11.49B USD0.35%$163.81-0.35%
iShares Russell 2000 ETFIWM16.94M0.02%79.88B USD0.19%$296.01+0.28%
Vanguard Morningstar Total Stock Market ETFVTI16.17M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 Value ETFIWN6.06M0.04%14.47B USD0.24%$224.62+0.40%
iShares Biotechnology ETFIBB4.95M0.05%10.72B USD0.44%$211.92-0.88%
Vanguard Extended Market ETFVXF4.7M0.00%93.7B USD0.05%$242.66+0.14%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP4.02M0.15%2.67B USD0.20%$67.695+0.29%
Fidelity Enhanced Small Cap ETFFESM3.15M0.05%6.03B USD0.28%$47.36+0.21%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Extended Market ETFVXFState Street SPDR S&P Kensho New Economies Composite ETFKOMPFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
